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CASE REPORT
CLINICAL CASE SERIES

3 Cases of Superior Vena Cava Syndrome
Following Percutaneous Right Ventricular
Assist Device Placement
John R. Vaile, BS,a J. Eduardo Rame, MD,b Rene J. Alvarez, MD,b Howard T. Massey, MD,c
Vakhtang Tchantchaleishvili, MD,c Alec Vishnevsky, MD,d Indranee N. Rajapreyar, MD,b Yevgeniy Brailovsky, DO,b
Mahek K. Shah, MDb

ABSTRACT
We present 3 cases of superior vena cava (SVC) syndrome following percutaneous right ventricular assist device (RVAD)
placement. Each case underscores the importance of early recognition of SVC syndrome in patients with percutaneous
RVAD insertion via the internal jugular vein and calls for heightened awareness of device-associated complications.
(Level of Difﬁculty: Advanced.) (J Am Coll Cardiol Case Rep 2021;3:1690–1693) © 2021 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).

S

uperior vena cava (SVC) syndrome is caused by

present, device-related SVC syndrome accounts for

partial or complete occlusion of the SVC, and in

up to 40% of all cases (1). Patients commonly present

recent years, the incidence of device-related

with facial and chest edema, dyspnea and cough, and

SVC syndrome has risen because of modern-day use

nonpulsatile distended neck veins (Figure 1). Depend-

of catheters, pacemakers, and deﬁbrillators. At

ing on the severity and location of the obstruction
and the presence of collateral venous drainage,

LEARNING OBJECTIVES

patients may also experience varying degrees of

 To recognize the development of SVC syndrome in patients with a dual-lumen percutaneous RVAD.
 To discuss predisposing risk factors to the
development of a superior vena caval
obstruction.
 To discuss management strategies in patients with SVC syndrome following placement of a dual-lumen percutaneous RVAD.

neurological (eg, headache, blurred vision), laryngopharyngeal (eg, glossitis), and upper extremity (eg,
edema) sequelae (1). In this case series, we report 3
cases of SVC syndrome following implantation of
the percutaneous dual-lumen ProTek Duo (Tandem
Life) right ventricular assist device (RVAD). We review recent literature on postsurgical and iatrogenic
causes of SVC syndrome and approaches for preventing and managing device-associated SVC syndrome.
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POSTSURGICAL AND IATROGENIC CAUSES

recognition

OF SVC SYNDROME

associated SVC syndrome (4).

AND ACRONYMS

SVC syndrome can arise in postsurgical settings or as

CLINICAL SUMMARY

CVP = central venous pressure

and

management

of

device-

ABBREVIATIONS

ICD = implantable cardioverter

a consequence of iatrogenic obstruction to venous

deﬁbrillator

drainage. Currently, heart transplantation and ven-

PATIENT 1. A 61-year-old man presented with

tricular assist devices may be used in end-stage heart

restrictive cardiomyopathy with biventricular

failure that is unresponsive to interventional treat-

failure

ments. Although bicaval anastomosis during heart

transplantation (OHT). The patient had a

transplantation is preferred because of anatomic and

dual-chamber

hemodynamic beneﬁts, this method effectively limits

deﬁbrillator

the distensibility of the SVC to the circumference of

following

the suture line and may precipitate SVC syndrome

esophageal echocardiogram (TEE) revealed a

TEE = transesophageal

with post-transplant RVAD use (2). Although un-

moderately dilated right ventricle (RV) with

echocardiogram

common, iatrogenic injury to the brachiocephalic

normal function. Postoperative day 2, the patient

venous system after heart transplant surgery can also

became profoundly hypotensive and unresponsive to

lead to obstructed venous return.

vasopressors, and because of high central venous

and

underwent

orthotopic

implantable
(ICD)

OHT.

A

that

heart

cardioverterwas

removed

postoperative

trans-

LVAD = left ventricular assist
device

OHT = orthotopic heart
transplantation

RVAD = right ventricular assist
device

SVC = superior vena cava

Although both postsurgical and iatrogenic causes

pressure (CVP) and RV dysfunction, the patient un-

of SVC syndrome can develop secondary to a disrup-

derwent RVAD extracorporeal membrane oxygena-

tion in hemodynamic stability (eg, vena caval steno-

tion. Approximately 30 hours later, the patient had

sis, hypercoagulability), scant literature has reported

marked swelling of the head and upper extremities

the onset of SVC syndrome after percutaneous RVAD

and a CVP of 45 mm Hg (Figure 2). The patient un-

cannulation via the right internal jugular vein (3). As

derwent immediate surgery for explantation of the

the frequency of percutaneous RVAD support in-

percutaneous RVAD and was converted to a central

creases due to ease of use, it is critical to discuss

surgical RVAD system, which was indicated following

F I G U R E 1 Clinical Signs of Superior Vena Cava Syndrome

Device-associated venous congestion causes neurological, laryngopharyngeal, and upper extremity sequelae. Created with BioRender.com.
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F I G U R E 2 Superior Vena Cava Syndrome Presentation After

DIAGNOSIS AND MANAGEMENT

Percutaneous Cannulation

The diagnosis of SVC syndrome is accomplished using
clinical picture and supplementary imaging modalities

like

chest

radiography,

contrast-enhanced

computed tomography scanning, duplex ultrasound,
conventional

catheter-based

digital

subtraction

venography, and magnetic resonance venography (1).
These tools grade the severity of the syndrome, which
is critical for informing initial management of the
patient.
For

nonmalignant

causes

of

SVC

syndrome,

including placement of a dual-lumen cannula, there
are several strategies for preventing venous congestion. In the setting of transplant, preoperative SVC
imaging can reveal anatomical variance in caval diPatient 1 presented with massive facial edema and signiﬁcant
swelling of the upper extremities and central venous pressure
of 45 mm Hg.

ameters; signiﬁcant discrepancy between host and
donor may increase risk for bicaval stenosis and
subsequent venous congestion. Likewise, we suggest
performing a venogram before RVAD placement in
patients with preexisting leads or central lines

refractory RV failure and SVC syndrome. After management, signs of SVC syndrome resolved, and the
patient survived to discharge.

because it may reveal subclinical stenosis. Similarly,
venous obstruction can be circumvented via imaging
of the SVC-RA junction among patients before device
placement; however, this approach poses a signiﬁcant

PATIENT 2. A 55-year-old man presented with acute

challenge because of poor validation of ranges for

decompensated left ventricular systolic heart failure

cross-sectional radiographic sizing across different

and cardiogenic shock that required an intra-aortic

imaging modalities (5).

balloon pump; he underwent LVAD and RVAD im-

In addition, the SVC is a compliant vasculature,

plantation. One week before LVAD placement, the

and its sizing is likely dependent on the hemody-

patient’s biventricular ICD was removed because of

namic status at the time of measurement. More

sepsis. Shortly after, central RVAD support was

informative imaging techniques may be accom-

switched to percutaneous support with no complica-

plished via computed tomography venography, but

tions. Approximately 45 hours following placement of

this approach carries a substantial radiation dose and

the device, the patient exhibited rapidly progressive

is poorly validated because venous size chieﬂy de-

head and neck swelling suggestive of SVC syndrome.

pends on intrathoracic pressure and volume status

After removal of a preexisting left internal jugular

(6). An alternative monitoring technique is to mea-

central venous line, the patient experienced improved

sure CVP through percutaneous catheterization via

facial edema, and signs of SVC syndrome resolved.

the left internal jugular or brachiocephalic vein using

PATIENT 3. A 50-year-old man with a history of

a 4-F to 7-F catheter. If high CVP is observed despite

HeartMate II explant for recovery presented with

proper device placement, clinical vigilance might be

recurrence of heart failure with a reduced left ven-

key to identifying development of SVC syndrome. At

tricular ejection fraction of 10% and associated RV

our institution, SVC syndrome was noted in 3 of 22

dysfunction. After implantation of LVAD and RVAD

(13.6%) device implants. We hypothesize that design

support, the patient experienced facial edema, orbital

modiﬁcations to facilitate drainage from the portion

swelling, and underwent emergent venogram that

of the RVAD cannula that is proximal to the cavo-

showed near occlusion of the SVC (Figure 3, Videos 1

atrial junction can provide adequate decompression.

and 2). Despite clinical improvement during the

Venous scarring from preexisting intravascular

subsequent 3 hours, RVAD support was removed, and

leads may result in reduced distensibility and may

signs of SVC syndrome resolved shortly thereafter.

precipitate venous congestion after percutaneous

The patient had a dual-chamber ICD during RVAD

RVAD cannulation. For example, SVC syndrome

placement and removal, which might have contrib-

following pacemaker implantation can occur sec-

uted to reduced SVC distensibility.

ondary to the formation of vegetations or via
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F I G U R E 3 Venography at the Time of Clinical Signs of Superior Vena Cava Syndrome

(A) Venogram revealed near-occlusion of the superior vena cava after device implantation. (B) Digital subtraction venography shows
prominent collateralization proximal to the occlusion.

thrombosis after endothelial disruption (7). In all 3

venous catheter within the left internal jugular and

cases, the patients had longstanding intravascular

subclavian venous system. By considering multiple

leads in place, and 2 patients had leads removed

etiologies for SVC syndrome, we hypothesize that

before cannulation. Moreover, we noted develop-

appropriate RV support and early recognition of SVC

ment of SVC syndrome within 48 hours in each pa-

syndrome

tient.

obstruction.

Ultimately,

if

there

is

concern

for

SVC

are

critical

for

preventing

venous

syndrome following the use of percutaneous RVAD
support, central surgical RVAD conversion can be
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